U.S. VCs Are Betting on Chinese Biotech Before the Data Even Exists
U.S. venture capital firms are embedding in Chinese labs and writing checks before research data is even published. The strategy has produced billion-dollar exits, but the geopolitical risks are as big as the potential rewards.
Imagine placing a bet on a racehorse before anyone's even seen it run. That's essentially what some U.S. venture capital firms are doing in Chinese biotech right now: writing checks before the research data is even published.
It sounds reckless. It might be brilliant.
The New Gold Rush Has a Lab Coat
American VCs have always loved getting in early. But "early" used to mean Series A, maybe seed stage. Now, firms like RA Capital are literally embedding themselves inside Chinese laboratories, forming relationships with scientists, and investing before the research sees daylight. The strategy is called moving "upstream," and it's reshaping how biotech deals get done across the Pacific.
Why the urgency? Because the competition is brutal. Chinese VCs are actively discouraging publication in some cases, hoping to lock up promising assets before Western investors even know they exist. If you wait for the journal article, you've already lost.
The CAR-T therapy Carvykti earned FDA approval in 2022. RA Capital also invested in Gracell Bio, which AstraZeneca scooped up for $1.2 billion in 2024. Those aren't small wins; those are portfolio-defining home runs.
China's Biotech Boom, by the Numbers
To understand why U.S. money keeps flowing east despite every geopolitical headwind imaginable, you need to see the scale of what's happening.
Chinese biotech out-licensing hit $135.7 billion in 2025, nearly ten times the $13.9 billion recorded in 2021. And 2026 is running even hotter: Q1 alone generated $60 billion in deal value.
China now accounts for roughly half of all global biotech licensing deal value. One-third of new compounds in global pharma pipelines originate from Chinese companies. This isn't a sideshow anymore. It's the main event.
The average deal size tells its own story. Average upfront payments have ballooned from $52 million in 2022 to $172 million today. As one analyst put it, "it's not a bargain basement anymore."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Picture two restaurants. One takes 90 minutes to make your meal and charges $50. The other serves the same dish in an hour for $35. Both are good. Which one gets the lunch crowd?
Chinese biotech operates at significantly lower cost than U.S. counterparts and can reach the market 50 to 100 percent faster. For Big Pharma companies staring down patent cliffs (the moment their blockbuster drugs lose exclusivity and generic competition floods in), Chinese-developed candidates are incredibly attractive.
The innovation pipeline is deep, too. Chinese firms are major players in antibody-drug conjugates (ADCs). They're also pushing ahead in bispecific antibodies, targeted protein degraders, and cell therapies. In 2025, Chinese biotechs inked more billion-dollar-plus deals (35) than American companies did.
Orbimed has emerged as the most active U.S. firm on the ground, maintaining its China presence even as others retreated during COVID and rising tensions. Foresite Capital has pointed to the broader market recovery, noting the Hang Seng Biotech Index climbed 64% in 2025.
The Deals That Prove the Point
The mega-deals keep coming, and they keep getting bigger.
AstraZeneca signed a deal with CSPC Pharmaceutical worth up to $18.5 billion, including $1.2 billion upfront for obesity and diabetes programs. GSK partnered with Hengrui in a deal potentially worth $12.5 billion, covering a COPD drug and 11 additional candidates. AbbVie locked up a cancer-focused agreement with RemeGen valued at up to $5.6 billion.
These aren't speculative bets on unproven science. Every major Western pharma company participated in China-origin deals during 2025. The desperation to refill pipelines is real, and Chinese biotechs are filling the void.
The Part Where Everything Gets Complicated
Investing in Chinese biotech before data is published sounds exciting until you think about what could go wrong. And there's a lot that could go wrong.
The BIOSECURE Act, passed through a defense spending bill in late 2025, bars U.S. agencies and contractors from working with designated Chinese biotech companies. New export controls imposed in January 2025 restrict certain biotech tools from reaching China. Congress is actively pushing outbound investment screening that could directly target VC dollars flowing into Chinese firms.
Then there's the data problem. Chinese clinical trials offer early proof signals because patient recruitment is fast and pools are large. But differences in patient populations, adverse event reporting, and standard-of-care medications create real questions about whether results will replicate in Western patients. The FDA still requires majority U.S. patient data for approvals.
The legal landscape adds another layer. Variable Interest Entity (VIE) structures, the corporate architecture most foreign investors use to access Chinese companies, face growing Congressional scrutiny over national security concerns. And China's own regulations on cross-border data transfers make accessing unpublished research even trickier.
Pre-publication investing amplifies all of these risks. Without published, peer-reviewed data, investors are relying on relationships, on-the-ground expertise, and a healthy dose of trust. Getting duped by overpromising early-stage science is a universal risk in biotech; doing it across geopolitical fault lines, in labs where language and cultural barriers exist, takes that risk up several notches.
So Is This Smart or Crazy?
Probably both, which is sort of the defining feature of venture capital.
The math is compelling. China's biotech sector produces genuine innovation at lower cost and faster speed. Deal pricing has converged with Western levels in 2025–2026, even as valuations rise. For a VC willing to do the homework (building local networks, hiring on-the-ground teams, running exhaustive IP audits), the risk-adjusted returns can be enormous.
But the geopolitical window could narrow at any moment. A single executive order, a new round of sanctions, or an escalation in U.S.-China tensions could freeze deal flow overnight. Domestic Chinese VC funding has already fallen to a seven-year low, pushing more reliance on foreign partnerships. If American capital gets cut off, it creates problems on both sides.
Experts recommend treating Hong Kong as a financial gateway, focusing on next-generation differentiation rather than fast-follower assets, and building milestone-based deal structures that manage downside risk. The days of casually "shopping" in China's biotech market are over; what's required now is serious, audited diligence.
For the VCs willing to do that work, the rewards could define the next decade of biotech investing. For those who skip the homework and chase hype into unpublished Chinese lab notebooks? Well, that racehorse might not run so fast after all.
Clinical & Regulatory4 min read
From $100M IPO to Liquidation in Five Years
IO Biotech went from a $100M IPO and "most innovative biotech" honors to total Chapter 7 liquidation in five years, all because its cancer vaccine trial missed statistical significance by the thinnest of margins. It's the most brutal cautionary tale in immuno-oncology right now.
